Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm (MPN)-Associated Intermediate- or High-Risk Myelofibrosis (MF) Resistant or Intolerant to Ruxolitinib: An Updated Analysis of the Phase II JAKARTA2 Study
作者
Claire Harrison,Nicolaas Schaap,Alessandro M. Vannucchi,Jean‐Jacques Kiladjian,Éric Jourdan,Richard T. Silver,Harry C. Schouten,Francesco Passamonti,Sonja Zweegman,Moshe Talpaz,Srđan Verstovšek,Torsten Gerike,Shelonitda Rose,Mingyu Li,Tymara Berry,Carrie Brownstein,Ruben A. Mesa